Justine Dell’Aringa is director of Translational Medicine at Bristol Myers Squibb (BMS) where she leads a team of researchers at the organization's Immuno-Oncology and Cell Therapy Thematic Research Center. 

Teri Foy, Ph.D, is the Senior Vice President of Research and Early Development. She oversees a team of researchers working tirelessly on translating scientific advances in immune effector cell-based therapies into treatments for hematological and solid cancers.

Today, PhRMA released a new report covering 549 medicines in development to potentially treat disorders of the blood, including blood cancers.